Compare IMMR & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | TNYA |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | 8 | 70 |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 171.4M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | TNYA |
|---|---|---|
| Price | $6.28 | $0.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $5.33 |
| AVG Volume (30 Days) | 461.6K | ★ 4.7M |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $303.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $0.43 |
| 52 Week High | $8.15 | $2.35 |
| Indicator | IMMR | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 47.05 |
| Support Level | $5.78 | $0.65 |
| Resistance Level | $6.39 | $0.82 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 44.01 | 7.60 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.